Semaglutide Race: Torrent Grabs 38% Market Share

Why It Matters

The rapid capture of market share signals that format diversification and aggressive physician outreach can dominate a high‑growth therapeutic class, reshaping competitive dynamics in India’s GLP‑1 space.

Key Takeaways

• Torrent holds 38% of India’s generic semaglutide market
• Oral tablet launch drives strongest early sales surge
• Multi‑format strategy boosts physician adoption
• Generic semaglutide sales reached ~$5.3 million in April
• Anti‑obesity market projected to hit $48‑$60 million soon

Pulse Analysis

The expiry of Novo Nordisk’s semaglutide patent in March 2026 opened the Indian market to a wave of generics. Within a month, Torrent Pharma captured roughly 38% of the nascent market, translating to about ₹17 crore ($2 million) in sales for April. Overall generic semaglutide revenue hit ₹44 crore ($5.3 million), while total market sales—including the innovator—reached ₹89 crore ($10.7 million). Torrent’s rapid ascent underscores the advantage of swift regulatory filing, aggressive launch execution, and a robust supply chain that outpaces competitors still scaling production.

Torrent’s edge stems from offering semaglutide in oral tablets, reusable pens and disposable pens—a first among Indian manufacturers. Oral tablets have resonated with patients and physicians, prompting pharmacies to report 10‑15‑day supply gaps. The company’s unified branding—Semalix and Sembolic—simplifies prescribing across formats, while intensive doctor‑engagement campaigns have amplified market visibility. Furthermore, the company’s hybrid technology for oral formulation sidesteps Novo Nordisk’s Rybelsus patent, ensuring legal clearance while preserving bioavailability. By securing the oral niche and maintaining a consistent brand narrative, Torrent has converted formulation variety into tangible prescription volume.

India’s anti‑obesity market, valued at roughly ₹1,600 crore ($19 million) today, is projected to expand to ₹4,000‑5,000 crore ($48‑$60 million) within 18 months, driven by rising diabetes and weight‑loss demand. Analysts anticipate semaglutide will command 80% of the GLP‑1 segment, pressuring rivals such as Dr Reddy’s, Zydus and Sun Pharma to broaden their delivery options. The early success of Torrent illustrates how format diversification and aggressive physician outreach can secure market share in a fast‑moving therapeutic arena, setting a benchmark for future generic launches. Investors are watching the segment closely, as the high‑margin profile of GLP‑1 therapies could reshape profit dynamics for Indian pharma firms.